Long-term outcomes of hospitalized SARS-CoV-2/COVID-19 patients with and without
neurological involvement: 3-year follow-up assessment
Short title: Long-term outcomes of COVID-19 patients with neurological involvement
Anna Eligulashvili ¹ , Moshe Gordon ¹ , Jimmy S Lee ¹ , Jeylin Lee ¹ , Shiv Mehrotra-Varma ¹ , Jai Mehrotra-
Varma ¹ , Kevin Hsu ² , Imanyah Hilliard ¹ , Kristen Lee ¹ , Arleen Li ¹ , Muhammed Amir Essibayi ³ , Judy
Yee ¹ , David J Altschul ³ , Emad Eskandar ³ , Mark F. Mehler ⁴ , and Tim Q. Duong ^{1,*}
¹ Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York
² Department of Radiology, New York University Grossman School of Medicine, New York, New York
³ Department of Neurological Surgery, Montefiore Health System and Albert Einstein College of Medicine, Bronx,
New York
⁴ Department of Neurology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York
* Corresponding Author: Tim Duong, PhD, Department of Radiology, Albert Einstein College of
Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, tim.duong@einsteinmed.edu
Key words: long covid, post-acute sequelae SARS-CoV-2 infection (PASC), brain imaging, MRI,
computed tomography

22 ABBREVIATIONS

- 23 ALT: alanine aminotransferase
- 24 ARDS: acute respiratory distress syndrome
- 25 AST: aspartate transaminase
- 26 BNP: brain natriuretic peptide
- 27 BUN: blood urea nitrogen
- 28 CDM: Common Data Model
- 29 CHF: congestive heart failure
- 30 CI: confidence interval
- 31 CKD: chronic kidney disease
- 32 CNS: central nervous system
- 33 COPD: chronic obstructive pulmonary disease
- 34 CRP: C-reaction protein
- 35 CT: computed tomography
- 36 Cr: creatinine
- 37 DDIM: D-dimer
- 38 EMR: electronic medical record
- 39 HI: hyperintensity
- 40 HR: hazard ratio
- 41 INR: international normalized ratio
- 42 LDH: lactate dehydrogenase
- 43 Lymph: lymphocyte count
- 44 MACE: major adverse cardiovascular events
- 45 MAP: mean arterial pressure
- 46 MRI: magnetic resonance imaging
- 47 MVD: microvascular disease
- 48 OHDSI: Observational Health Data Sciences and Information
- 49 OMOP: Observational Medical Outcomes Partnership
- 50 OR: odds ratio
- 51 SBP: systolic blood pressure
- 52 SNF: skilled nursing facility
- 53 TNT: troponin-T
- 54 WBC: white blood cell count
- 55 WM: white matter

56 ABSTRACT

57 <u>Background and Objectives:</u> Acute neurological manifestations are a common complication of acute

58 COVID-19 disease. This study investigated the 3-year outcomes of patients with and without significant

59 neurological manifestations during initial COVID-19 hospitalization.

60

61 Methods: Patients infected by SARS-CoV-2 between March 1 and April 16, 2020 and hospitalized in the 62 Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up 63 data was captured up to January 23, 2023 (3 years post COVID-19). This cohort consisted of 414 64 COVID-19 patients with significant neurological manifestations and 1199 propensity-matched COVID-65 19 patients without neurological manifestations. Primary outcomes were mortality, stroke, heart attack, 66 major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. 67 Secondary outcomes were clinical neuroimaging findings (hemorrhage, active stroke, prior stroke, mass 68 effect, and microhemorrhage, white-matter changes, microvascular disease, and volume loss). Predictive 69 models were used to identify risk factors of mortality post-discharge. 70 71 Results: More patients in the neurological cohort were discharged to acute rehabilitation (10.54% vs 72 3.68%, p<0.0001), skilled nursing facilities (30.67% vs 20.78%, p=0.0002) and fewer to home (55.27%) 73 vs 70.21%, p<0.0001) compared to the matched controls. Incidence of readmission for any medical

74 reason (65.70% vs 60.72%, p=0.036), stroke (6.28% vs 2.34%, p<0.0001), and MACE (20.53% vs

75 16.51%, p=0.032) was higher in the neurological cohort post-discharge. Neurological patients were more

76 likely to die post-discharge (58 (14.01%) vs 94 (7.84%), p=0.0001) compared to controls (HR=2.346,

77 95% CI=(1.586, 3.470), p<0.0001). The major causes of death post-discharge were heart disease

78 (14.47%), sepsis (13.82%), influenza and pneumonia (11.18%), COVID-19 (8.55%) and acute respiratory

distress syndrome (7.89%). Factors associated with mortality after leaving the hospital were belonging to

80 the neurological cohort (OR=1.802 (1.237, 2.608), p=0.002), discharge disposition (OR=1.508, 95%

81 CI=(1.276, 1.775), p<0.0001), congestive heart failure (OR=2.281 (1.429, 3.593), p=0.0004), higher

- 82 COVID-19 severity score (OR=1.177 (1.062, 1.304), p=0.002), and older age (OR=1.027 (1.010, 1.044),
- 83 p=0.002). There were no group differences in gross radiological findings, except the neurological cohort
- 84 showed significantly more age-adjusted brain volume loss (p<0.05) compared to controls.
- 85
- 86 <u>Discussion:</u> COVID-19 patients with neurological manifestations have worse long-term outcomes
- 87 compared to matched controls. These findings raise awareness and the need for closer monitoring and
- timely interventions for COVID-19 patients with neurological manifestations.

89 INTRODUCTION

90	Severe acute neurological events – such as ischemic stroke, seizure, intracranial hemorrhage and
91	thrombosis, and encephalopathy – have been reported in COVID-19 patients(1-8). The causes of these
92	central nervous system (CNS) manifestations are multifactorial. There is conflicting evidence whether
93	SARS-CoV-2 infects neuronal cells, with some studies reporting neuronal invasion(9), while others report
94	no evidence of direct infection(10, 11). Additional studies suggest that a diffuse microvasculopathy may
95	ensue with endothelial compromise, micro-infarctions, subsequent micro-hemorrhages, and microglial
96	conglomerates with innate immune activation. Nonetheless, CNS manifestations could also arise from
97	secondary effects, such as from respiratory distress, cardiovascular stress, sepsis, hypercoagulation, and
98	host-mediated immune responses triggered by SARS-CoV-2 infection. Patients with neurological
99	complications have been shown to have worse acute COVID-19 outcomes compared to propensity-
100	matched controls(12). However, the long-term outcomes of COVID-19 survivors with CNS
101	manifestations are unknown.
102	The goal of this study was to evaluate the 3-year outcomes of COVID-19 patients with significant
103	neurological complaints that warranted neuroimaging during COVID-19 when compared with propensity-
104	matched controls without significant neurological complaints. Improved understanding of the long-term
105	outcomes of COVID-19 patients with CNS manifestations could help to identify at-risk patients and
106	enable timely interventions to address the potentially high burden of care among these COVID-19
107	survivors.
108	
109	METHODS
110	
111	Data sources
112	This observational study followed the STROBE guideline. This is a follow-up retrospective study
113	of a previously reported retrospective cohort study of adult patients(12) admitted to the Montefiore Health
114	System due to COVID-19 between March 01 and April 16, 2020 with confirmed SARS-CoV-2 infection

by real-time reverse transcriptase PCR-positive assay testing. Follow-up data was captured up to January
23, 2023 (3 years follow-up).

117 The original neurological cohort consisted of 636 hospitalized COVID-19 patients who 118 experienced various neurological signs and symptoms that warranted neuroimaging during COVID-19 119 hospitalization. Neurological involvement included acute stroke (confirmed by imaging), new or 120 recrudescent seizures, anatomic brain lesions (subdural hematoma, brain tumor, chronic infarction, or 121 nonspecific lesions), presence of altered mentation with evidence for impaired cognition or arousal, and 122 neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, 123 cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal orientation and 124 arousal signs). The original control group consisted of 1743 hospitalized COVID-19 patients by 3:1 125 propensity-matching for age and COVID-19 severity score who did not have significant neurological 126 issues during hospitalization. After excluding patients who died during hospitalization or were missing 127 from our database, the neurological cohort and control cohort had sample sizes of 414 and 1199 patients, 128 respectively. Note that the samples differed slightly from the original paper because a few additional 129 patients were found to meet the inclusion/exclusion criteria.

130

131 Data abstraction

132 Health data were extracted automatically from the electronic medical records as described 133 previously(13-18). De-identified health data were obtained for research after standardization to the 134 Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) version 6. OMOP 135 CDM represents healthcare data from diverse sources, which are stored in standard vocabulary 136 concepts(19), allowing for the systematic analysis of disparate observational databases, including data 137 from the electronic medical record (EMR), administrative claims, and disease classifications systems 138 (e.g., ICD-10, SNOWMED, LOINC, etc.). ATLAS, a web-based tool developed by the Observational 139 Health Data Sciences and Informatics (OHDSI) community that enables navigation of patient-level, 140 observational data in the CDM format, was used to search vocabulary concepts and facilitate cohort

141	building. Data were subsequently exported and queried as SQLite database files using the DB Browser for
142	SQLite (version 3.12.0). To ensure data accuracy, our team performed extensive cross validation of all
143	major variables extracted by manual chart reviews on subsets of patients(13-18).
144	
145	Discharge dispositions: Discharge disposition of survivors from COVID-19 hospitalization were
146	categorized as home (with or without home care), hospice, acute rehabilitation, skilled nursing facility
147	(SNF), and others (i.e., custodial care, supportive care, and psychiatric care).
148	
149	Data abstraction: Age, gender, race, ethnicity, comorbidities, and laboratory test data were extracted
150	from electronic medical records at follow-up extending to January 23, 2023. Incidence of stroke, heart
151	attack, major adverse cardiac events (MACE, defined as the composite of cardiovascular death, nonfatal
152	stroke, nonfatal myocardial infarction, new-onset nonfatal heart failure, thromboembolism and nonfatal
153	cardiogenic shock(20, 21)), reinfection, and readmission after COVID-19 discharge for any reason were
154	tabulated at 3-year follow-up. For non-survivors, the cause of death was ascertained via chart review and
155	categorized using the primary reason for death as reported on the death certificate.
156	Preexisting comorbidities included chronic obstructive pulmonary disease (COPD) and asthma,
157	diabetes, congestive heart failure (CHF), and chronic kidney disease (CKD). Vital signs and laboratory
158	data included temperature, systolic blood pressure (SBP), arterial pressure, D-dimer (DDIM),
159	international normalized ratio (INR), blood urea nitrogen (BUN), creatinine (Cr), sodium, glucose,
160	aspartate transaminase (AST), alanine aminotransferase (ALT), white blood cell count (WBC),
161	lymphocyte count (Lymph) ferritin (FERR), C-reactive protein (CRP), procalcitonin, lactate
162	dehydrogenase (LDH), brain natriuretic peptide (BNP), troponin-T (TNT), and arterial oxygen saturation.
163	Laboratory data for COVID-19 admission and at follow-up (most recent) were obtained.
164	
165	<u>COVID-19 disease severity score</u> : In-hospital COVID-19 disease severity scores(12) were the sum of five
166	components that range from 0 to 10 points, on admission: (1) age by decile (age greater than 60, 70, and

80 earned 1, 2, and 3 points, respectively), (2) mean arterial pressure (MAP) indicating hypotension
(MAP below 80, 70, and 60 earned 1, 2, and 3 points), (3) oxygen saturation below 94% indicating
impaired pulmonary function (1 point), (4) BUN greater than 30 indicating impaired renal function (1
point), and (5) INR greater than 1.2 and CRP greater than 10, indicating coagulopathy and inflammatory
response. Scores ranged from 0 to 10 with higher score reflecting worse COVID-19 disease severity.

173 Imaging assessment: Head computed tomography (CT) and brain magnetic resonance imaging 174 (MRI) examinations were assessed at three different time points: those obtained before their COVID-19 175 hospitalization (most recent), during COVID-19 hospitalization, or after COVID-19 hospitalization (most 176 recent) if available. Images were assessed by board-certified radiologists (K.H., J.L., each with at least 10 177 years of experience) and radiology residents (I.H., K.L., A.L.) under the supervision of the board-certified 178 radiologists, blinded to the patient cohort designation. To establish assessment criteria and the scoring 179 system, our board-certified radiologists and residents worked together to reach consensus by evaluating 180 over a dozen images. Two residents scored each image and at least one board-certified radiologist 181 reviewed and adjudicated. Major findings on both CT and MRI, documented for their absence or presence 182 of hemorrhage, active stroke, prior stroke, mass effect, and microhemorrhage (on MRI only). In addition, 183 white-matter (WM) change, microvascular disease (MVD), and volume loss on CT and MRI were graded 184 as 0 for normal or not present, 1 for mild, 2 for moderate, and 3 for severe, taking account the age of 185 patient. MRIs were additionally graded for extent of WM lesions or hyperintensities (HI) using the same 186 grading scale. Findings were tabulated for pre-, during and post COVID-19. In cases where patients had 187 both CT and MRI at a specific timepoint, MRI was used.

Finally, changes in imaging findings before and after COVID-19, if available, were assessed using the grading scale of 0: no change, ±1: mild change, ±2: moderate change, and ±3 severe change, with positive changes indicating worsening and negative indicating improvement between the two time points. Pre-COVID-19 images were used as a baseline if both pre- and during COVID-19 images were available.

193

Primary outcomes: Primary outcomes were mortality, stroke, heart attack, MACE, reinfection, and
 hospital readmission post discharge January 23, 2023 (3 years post COVID-19). Secondary outcomes
 were qualitative and score-based clinical neuroimaging findings, which included the absence or presence
 of hemorrhage, active stroke, prior stroke, mass effect, and microhemorrhage, as well as scores of WM
 changes, MVD, and volume loss.
 Associative models using logistic regression were employed to identify variables associated with

mortality after discharge. Input for age was a continuous variable. Input for discharge disposition status was a single variable. Input for COVID-19 severity scores was a continuous variable. The rest of the variables used in the model were categorical variables. Odds ratios (OR) and 95% confidential interval (CI) were computed. In addition, Kaplan-Meier curves were constructed and analyzed using GraphPad Prism, with the outcome event being classified as dead (death date) or alive (most recent patient encounter). The survival curves of the neurological and control cohorts were compared with the logrank test (Mantel-Cox) method, resulting in a log rank hazard ratio (HR), 95% CI, and p-value.

207

208 Statistical Analysis

Analysis of group differences of demographic and clinical variables employed χ^2 tests for categorical variables and two-tailed t-tests for continuous variables via the statistical library in RStudio. Analysis of associative variables was performed in RStudio using a logistic regression model. Statistical comparison of imaging scores and changes of scores from baseline (pre or during COVID-19 hospitalization) to follow-up (post-COVID-19 hospitalization) employed unpaired t-test. P<0.05 was considered statistically significant unless otherwise specified. Statistics were not adjusted for multiple comparison due to the exploratory nature of the study.

217 Standard Protocol Approvals, Registrations, and Patient Consents

218	This retrospective study using real world data was approved by our Institutional Review Board
219	(#2021-13658) with a waiver of informed consent. All methods were performed in accordance with
220	relevant guidelines and regulations pertaining to human subjects.
221	
222	Data Availability Statement
223	Reasonable request of data is available by contacting the corresponding author.
224	
225	RESULTS
226	Of the original neurological cohort of 636 patients, 414 were discharged alive and 371 returned to
227	our health system. Of the original control cohort of 1743, 1199 were discharged alive and 1071 returned
228	to our health system. The overall attrition rate was 10.60%.
229	
230	Discharge disposition
231	Figure 1 shows the discharge dispositions of the neurological and control cohorts stratified by
232	COVID-19 severity score. Patients with high severity scores were less likely to be discharged home and
233	more likely to be discharged to a SNF or hospice in both groups. However, there were relatively more
234	patients disposed to SNF and relatively fewer patients disposed to home in the neurological cohort
235	compared to the control cohort.
236	
237	Primary outcomes of neurological vs control cohort
238	Table 1 shows the profiles of the survivors at discharge grouped by neurological and control
239	cohorts. There were no significant group differences in age (69.71±15.80 vs 70.26±15.14, p>0.05),
240	female gender composition (44.93% vs 48.21%, p>0.05), all major comorbidities (p>0.05) and race and
241	ethnicity (p>0.05), except Black non-Hispanic (42.51% vs 36.03%, p=0.009), and Hispanic (33.57% vs
242	38.20%, p=0.047). More patients in the neurological cohort were discharged to acute rehabilitation
243	(10.54% vs 3.68%, p<0.0001) and SNF (30.67% vs 20.78%, p=0.0002) and fewer survivors in the

244 neurological cohort were discharged to home (55.27% vs 70.21%, p<0.0001) compared to the control 245 cohort. With respect to laboratory data, there were few group differences between those at admission and 246 at follow-up, as well as between groups (Supplemental Table 1). Some laboratory data at admission 247 were worse than those at follow-up and laboratory data of the neurological cohort was worse than those of 248 the control cohort. 249 Incidence of readmission (65.70% vs 60.72%, p=0.036), stroke (6.28% vs 2.34%, p<0.0001), and MACE (20.53% vs 16.51%, p=0.032) were significantly higher in the neurological cohort than the control 250 251 cohort. There were however no significant group differences in heart attack and reinfection after 252 discharge (all p>0.05). Mortality rates were also higher in the neurological cohort compared to the control 253 cohort at 0.5 years (7.73% vs 3.67%, p=0.0004), 1 year (9.18% vs 4.92%, p=0.0009), and 3 years 254 (14.01% vs 7.84%, p=0.0001). Kaplan-Meier survival analysis (Figure 2) showed that the neurological 255 cohort had a significantly lower survival probability than the control cohort at all timepoints (HR=2.346, 256 95% CI=(1.586, 3.470), p<0.0001). 257

258 *Outcomes versus COVID-19 severity scores*

259 **Supplemental Figure 1A** shows the distribution of COVID-19 severity scores in each cohort, 260 confirming proper propensity matching by severity score among survivors after COVID-19 261 hospitalization discharge. Primary outcomes were analyzed with respect to COVID-19 severity score for 262 survivors and non-survivors post discharge (Figure 1B-F). Readmission for any medical reasons were 263 similar among all severity scores for both cohorts. Incidence of stroke was high for all severity scores in 264 the neurological cohort but was generally lower for matching scores in the control cohort. Incidence of 265 heart attack also appeared to be trending upwards as severity score increased for both cohorts. The 266 percent of patients who had MACE was distributed over a range of scores for both cohorts, with a higher 267 COVID-19 severity scores showing a slightly higher percentage of patients with MACE at follow-up. 268 Non-survivors at follow-up had higher COVID-19 severity score compared to survivors.

269

270 *Cause of death post COVID-19 discharge*

There were no group differences in cause of death between patients belonging to neurological and control cohorts (p>0.05). Beside the unknown cause of death (30.92%), the major causes of death after discharge were heart disease (13.79% neurological, 15.38% control), sepsis (8.62%, 17.58%), influenza and pneumonia (13.79%, 9.89%), COVID-19 (10.34%, 7.69%) and acute respiratory distress syndrome (ARDS) (10.34%, 6.59%) (**Table 2**).

276

277 <u>Survivors and non-survivors post discharge</u>

Table 3A compared the profiles of survivors and non-survivors in the neurological and control
cohorts post discharge. There are few differences of survivors and non-survivors between cohorts. Both
within the neurological and control cohorts, non-survivors were significantly older and had higher
COVID-19 severity score compared to survivors. Although no differences in comorbidities were observed
in the neurological cohort, control non-survivors had higher incidence of hypertension, diabetes, CHF,
and CKD. Both neurological and control non-survivors were less likely to be discharged home and more
likely to be discharged to SNF.

285

286 <u>Risk factors for mortality after discharge</u>

A logistic regression model found 5 significant variables associated with mortality post discharge

288 (Table 3B). These variables were belonging to the neurological cohort (OR=1.802 (1.237, 2.608),

289 p=0.002), discharge disposition (OR=1.508, 95% CI=(1.276, 1.775), p<0.0001), congestive heart failure

290 (OR=2.281 (1.429, 3.593), p=0.0004), COVID-19 severity score (OR=1.177 (1.062, 1.304), p=0.002),

291 and age (OR=1.027 (1.010, 1.044), p=0.002). Male gender (OR=1.387 (0.963, 2.004), p=0.08) was

- trending significance.
- 293

294 *Imaging findings*

295	Table 4A summarizes the pre-, intra-, and post- COVID-19 neuroradiological findings. The
296	numbers of pre-, intra-, and post- COVID-19 patients with imaging studies varied. Of those with imaging,
297	about 20% were MRI and 80% were CT. For qualitative assessment, 30-40% of patients had prior strokes
298	for all three time points, whereas the presence of hemorrhage, active stroke and/or mass effect were
299	relatively low (0-10% with most around 5%). There were, however, no group differences in these
300	qualitative findings for all three time points (p>0.05).
301	For score-based assessment, the average scores for age-appropriate WM change and MVD were
302	about 1 (mild abnormality), and the average scores for age-appropriate volume loss and WM lesions were
303	about 0.5 (no to mild abnormality). Distribution of scores were similar between groups. There were no
304	differences in scores between groups, except for volume loss post COVID-19 (average score: 0.72 ± 0.71
305	neurological vs 0.57±0.69 control, p=0.045; and score of 0: 42.36% neurological vs. 53.78%, p=0.037).
306	Table 4B shows the changes in imaging findings between baseline (pre- or intra-COVID-19) and
307	follow-up (post-COVID-19). There were significant increases in the incidence of active stroke
308	(neurological: 6.25%, p=0.021; control: 3.82%, p=0.039), prior stroke (12.5%, p=0.0003; 9.55%,
309	p=0.002), and microhemorrhage (7.14%, p=0.012; 6.37%, p=0.004) between the two time points,
310	indicative of age-related effects. There were, however, no group differences (p>0.05 for all).
311	WM changes (neurological: 0.12±0.44, p=0.006; control: 0.18±0.46, p<0.0001), MVD
312	(0.15±0.41, p=0.0001; 0.18±0.46, p<0.0001) and volume loss (0.15±0.41, p=0.0001; 0.17±0.42,
313	p<0.00101) were higher (worsening) post-COVID compared to baseline for both neurological and control
314	cohorts. There were, however, also no group differences (p>0.05 for all).
315	
316	DISCUSSION
317	This study investigated the 3-year outcomes of hospitalized COVID-19 patients with and without
318	major neurological issues. The major findings are: i) COVID-19 patients with significant neurological
319	issues that warranted neuroimaging were more likely to be discharged to acute rehabilitation and skilled
320	nursing facilities compared to matched controls, ii) the neurological cohort had higher mortality rates

321	after discharge (HR=2.346, p<0.0001) compared to controls, iii) the incidence of readmission, stroke, and
322	MACE, but not heart attack or reinfection, were higher in the neurological cohort at 3 years follow-up, iv)
323	the primary causes of death after discharge for both cohorts were heart failure, sepsis, influenza and
324	pneumonia, COVID-19 and ARDS, v) patients who died post-discharge were significantly older, more
325	likely to be male, had higher COVID-19 severity score, and those were sent to skilled nursing facilities at
326	discharge compared to survivors, vi) there were no group differences in gross radiological findings with
327	respect to hemorrhage and stroke, except the neurological cohort showed significantly more age-
328	appropriate volume loss than the control cohort.
329	
330	Disposition: Approximately half of the neurological patients and one-thirds of the control patients were
331	discharged to SNF, acute rehabilitation, or hospice. These findings indicated that many COVID-19
332	patients were not functionally independent after discharge(22-24), especially those in the neurological
333	cohort. Few studies today have reported home, SNF, and acute rehabilitation discharge rates after
334	COVID-19 hospitalization(22-26). These findings suggest that patients in the neurological cohort likely
335	needed more follow-up medical care at discharge.
336	
337	Primary outcomes: The majority (60-65%) of all neurological and control patients were readmitted to our
338	health system for medical reasons over 3 years. This is not surprising for our cohort due to advanced age
339	and high prevalence of comorbidities, although it is higher than reported in some studies(27-30).
340	Readmission could be due to age-related illness or medical conditions exacerbated by COVID-19. The
341	neurological cohort had a higher readmission rate than the control cohort, suggesting that a higher burden
342	of disease during COVID-19 hospitalization may be associated with a higher probability of re-
343	hospitalization.
344	The incidence of stroke was 2-6% and of heart attack was 4-5% in both groups. The incidence of
345	MACE after discharge (16-20%) was higher than other reported previously in COVID-19 who did not
346	have neurological issues(18). A few studies have suggested COVID-19 exerts long-term cardiovascular

effects(16, 31-33), consistent with a disease that affects the cardiovascular system and thus can result in
MACE after severe infection warranting hospitalization. Approximately 4-5% of both cohorts
experienced COVID-19 re-infection. This rate of re-infection is slightly higher than what is reported
elsewhere(34, 35). The higher rate of re-infection may be attributed to the urban setting of congested
environs, high rates of comorbidities and healthcare disparities associated with lower socioeconomic
status(36).

353 Of those who died post-discharge, more than half died within the first 0.5 years in both groups, 354 suggesting that most of these deaths were likely COVID-19 related. The cumulative mortality rates of the 355 neurological and control cohorts at 3 years post-discharge were 14% and 8%, respectively. The marked 356 mortality rate differences between groups are highlighted by the Kaplan-Meier analysis. Those who died 357 at follow-up in both groups were 8 years older and more likely to be male as compared to survivors. 358 Elderly patients may be more prone to exhibiting early neurologic symptoms because of limited cognitive 359 reserve. This is widely seen in other medical conditions such as urosepsis. Patients presenting with early 360 neurologic compromise could be a harbinger of susceptibility for higher mortality across other disease 361 states. Male gender has been previously reported to have worse acute in-hospital outcomes, including 362 higher rate of multi-organ injury, critical care illness, and in-hospital mortality(37-40). Here we reported 363 male gender also had worse long-term outcomes post COVID-19 discharge.

364 Logistic regression model identified discharge disposition to be the top risk factor for post-365 discharge mortality, followed by CHF, COVID-19 severity score, belonging to the neurological cohort, 366 and age. CHF was the only comorbidity that was significantly associated with post-discharge mortality. 367 Patients who had more severe COVID-19 disease were also more likely to die post discharge. Belonging 368 to the neurological cohort was also independent risk factor for post-discharge mortality. It is not 369 surprising that advanced age is associated with higher post-discharge mortality, but advanced age ranked 370 lower than other variables mentioned above. Note that OR for male gender was trending significance and 371 we predicted that large sample sizes could result in significant findings. Taken together, these findings

underscore the independent risk factors that contributed to post discharge mortality and notably belongingto the neurological cohort is a significant independent risk factor.

374

375 *Cause of Death:* The causes of death were similar between neurological and control cohorts, consistent 376 with findings using logistic regression in which belonging to neurological cohort was an important but not 377 the most important associative variable of post COVID-19 discharge mortality. The primary known 378 causes of death in both the neurological and control cohorts were heart disease, sepsis, influenza and 379 pneumonia, COVID-19, and ARDS. Sepsis, pneumonia, and ARDS might be related to or be triggered by 380 COVID-19, although they could also be a result of other medical events. It is possible that COVID-19 as 381 a cause of death was underestimated as a result of imprecise categorization in the death certificates. Note 382 that about one-third of the causes of death were specified as unknown on the death certificates. It is 383 possible that some patients died of senescence and no primary cause of death was noted. 384 385 Imaging Findings: Age of patient was taken into consideration when assessing neuroradiological 386 findings. Imaging findings of control and neurological patients displayed differential profiles of

387 abnormalities that were consistent with age and comorbidities in this population. The differences in

388 radiological findings between baseline and follow-up showed age-related effects. However, there were

generally no group differences in qualitative nor score-based findings, except that the neurological cohortshowing higher volume loss post-COVID-19 compared to controls.

391 Several case reports and few cohort studies have identified reduction in grey-matter thickness, 392 ischemic stroke, decrease in global brain size, cerebral microstructural changes, and persistent WM 393 changes associated with COVID-19(41-47). There is likely some reporting bias in case or case-series 394 studies as positive clinical imaging findings associated with COVID-19 are more likely to be reported. 395 Most of these studies do not compare findings to baseline, which makes it difficult to discern whether 396 imaging abnormalities were pre-existing or a consequence of COVID-19 disease. None of these studies 397 employ a scoring system to accentuate the degree of abnormality. Our study is novel because of its large

and diverse patient population, long follow-up times, the use of a scoring system, and comparison
between baseline and follow-up studies to 3 years post-discharge. It is possible that COVID-19 related
changes in the brain anatomy and structure could take time to manifest, and we predict that some COVID19 patients will likely experience accelerated aging and high incidence of age-related disorders. Brain
imaging is important because it could provide neural correlates of post-COVID-19 neurological sequela,
which include, but is not limited to, neurological symptoms, neurocognitive symptoms, fatigue, memory
loss, anxiety, depression, and post-traumatic stress disorder(8, 48-50).

405

406 Taken together these current observations contribute new insights concerning our understanding 407 of the longitudinal effects of neurological involvement in long COVID. In terms of nervous system 408 involvement, persistence and evolution, there are likely bidirectional interactions between the nervous and 409 the immune systems that orchestrate a composite pro-inflammatory, hypercoagulable, hypoxemic, and 410 immune dysregulated state(7). In addition, these dynamic processes could contribute to accelerated brain 411 aging, stress pathway-mediated neural injury responses, features of traumatic encephalopathy, 412 demyelination, neurodegeneration, and accompanying preferential cortical atrophy as we have identified 413 in this study. Moreover, multiple communication routes between the central and peripheral nervous 414 systems and the body in long COVID create systemic organ system, tissue and cellular interfaces that 415 impair organismal homeostasis to give rise to persistent deregulated regenerative and plasticity responses. 416 These pathological processes promote chronic multi-organ dysfunction and can lead to a spectrum of 417 stressor states that predispose to organ fibrosis, tissue degeneration and even dysplastic and neoplastic 418 conditions with associated metabolic derangement, immune dysregulation, inflammatory processes, and 419 additional features of SARS-CoV-2/COVID-19-mediated dyshomeostasis syndrome, including 420 proteotoxicity and protean epigenetic derangements. Such biological contingencies suggest that the 421 multifactorial nature of the neurological manifestations of COVID-19 may put patients at higher risk of 422 long-term functional disabilities and death as we have currently observed. Importantly, our increasing 423 understanding of the nature of the deregulation of dynamic nervous system-systemic crosstalk displayed

in response to SARS-CoV-2 may allow us to devise innovative and interdisciplinary mitigation strategies
to alleviate the long-term sequelae preferentially caused by early neurological involvement in COVID-19.

427 Limitations

428 This is one of the largest cohort studies of imaging findings and one of the longest follow-up 429 studies of COVID-19 survivors. This study however has several limitations. Our patient cohort was 430 limited to patients infected with COVID-19 during the first wave of the pandemic, when hospitals were 431 overburdened, COVID-19 vaccines were not yet available, and COVID-19 treatments were limited. The 432 patient profiles (i.e., age composition) might differ from those of subsequent waves. Additionally, the 433 selection of patients was subjective and may have introduced selection bias. In building the control 434 cohort, propensity scoring only factored in age and COVID-19 severity to remain consistent with the 435 index study.

436 Although the attrition is low (10%), patients who did not return to our health system could not be 437 studied. While it is possible that returning patients were more likely to have more severe COVID-19, our 438 patient data consisted of those who returned for any medical reasons, including regular checkups. On the 439 other hand, those who did not return might have expired. Our current study was not powered to address 440 differences due to race and ethnicity because our cohort consisted of large proportions of Blacks and 441 Hispanics but low proportions of other race and ethnic groups. Imaging sample sizes were small because 442 not all patients had imaging performed at all three time points. The mixture of MRI and CT, which may 443 have different sensitivities for various accompanying pathologies. More sophisticated imaging methods 444 are warranted. Future studies should compare results with those of the general population without SARS-445 CoV-2 infection. Other factors such as reinfection, COVID-19 vaccination status, and influenza 446 vaccination status could affect long-term outcomes. As with any retrospective study, there could be other 447 unintended patient selection biases and unaccounted for confounders.

448

449 **Conclusions**

- 450 Patients with significant neurological findings during COVID-19 hospitalization were more likely
- 451 to have worse outcomes at 3-year follow-up compared to propensity matched controls. Improved
- 452 understanding of the long-term outcomes of COVID-19 patients with neurological involvement could
- 453 help to develop effective screening methods and innovative interventions to address the potentially high
- 454 burden of care among these COVID-19 survivors.

455 Acknowledgments

- 456 None
- 457 Study Funding
- 458 No targeted funding reported.

459 **REFERENCES**

460 Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary 1. 461 function and related physiological characteristics of COVID-19 survivors three months after recovery. 462 EClinicalMedicine. 2020;25:100463. 463 Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. 2. 464 Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 465 2020. 466 3. Rubin R. As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts. JAMA. 2020. 467 Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom 4. 468 Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a 469 Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly 470 Rep. 2020;69(30):993-8. 471 5. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients 472 After Acute COVID-19. JAMA. 2020;324(6):603-5. 473 Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID 6. 474 in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. 475 Anand H, Ende V, Singh G, Qureshi I, Duong TQ, Mehler MF. Nervous System-Systemic 7. 476 Crosstalk in SARS-CoV-2/COVID-19: A Unique Dyshomeostasis Syndrome. Front Neurosci. 477 2021;15:727060. 478 Iosifescu AL, Hoogenboom WS, Buczek AJ, Fleysher R, Duong TQ. New-onset and persistent 8. 479 neurological and psychiatric sequelae of COVID-19 compared to influenza: A retrospective cohort study 480 in a large New York City healthcare network. Int J Methods Psychiatr Res. 2022;31(3):e1914. 481 9. Song E ZC, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai 482 Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM, 483 Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, 484 Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farhadian SF, Huttner A, Seilhean D, Renier 485 N, Bilguvar K, Iwasaki A. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 486 2021;218(3):e20202135. 487 Brann DH TT, Weinreb C, Lipovsek M, Van den Berge K, Gong B, Chance R, Macaulay IC, 10. 488 Chou HJ, Fletcher RB, Das D, Street K, de Bezieux HR, Choi YG, Risso D, Dudoit S, Purdom E, Mill J, 489 Hachem RA, Matsunami H, Logan DW, Goldstein BJ, Grubb MS, Ngai J, Datta SR, Non-neuronal 490 expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying 491 COVID-19-associated anosmia. Sci Adv. 2020;6(31):eabc5801. 492 Camargo-Martínez W L-MI, Escobar-Collazos A, Navarro-Coronado A, Moscote-Salazar L, 11. 493 Pacheco-Hernández A, Janjua T, Bosque-Varela P. Post-COVID 19 neurological syndrome: Implications 494 for sequelae's treatment. J Clin Neurosci. 2021;88:219-25. 495 Eskandar EN, Altschul DJ, de la Garza Ramos R, Cezavirli P, Unda SR, Benton J, et al. 12. 496 Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19. Neurology. 497 2021;96(11):e1527-e38. 498 13. Hoogenboom WS, Pham A, Anand H, Fleysher R, Buczek A, Soby S, et al. Clinical 499 characteristics of the first and second COVID-19 waves in the Bronx, New York: A retrospective cohort 500 study. Lancet Reg Health Am. 2021;3:100041. 501 14. Hoogenboom WS, Fleysher R, Soby S, Mirhaji P, Mitchell WB, Morrone KA, et al. Individuals 502 with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from 503 COVID-19 - A fifteen hospital observational study in the Bronx, New York. Haematologica. 2021;106(11):3014-6. 504 Lu JY, Ho SL, Buczek A, Fleysher R, Hou W, Chacko K, et al. Clinical predictors of recovery of 505 15. 506 COVID-19 associated-abnormal liver function test 2 months after hospital discharge. Sci Rep. 507 2022;12(1):17972.

- 508 16. Lu JY, Wilson J, Hou W, Fleysher R, Herold BC, Herold KC, et al. Incidence of new-onset in-
- hospital and persistent diabetes in COVID-19 patients: comparison with influenza. EBioMedicine.2023;90:104487.
- 511 17. Lu JY, Hou W, Duong TQ. Longitudinal prediction of hospital-acquired acute kidney injury in 512 COVID-19: a two-center study. Infection. 2022;50(1):109-19.
- 513 18. Lu JY, Boparai MS, Shi C, Henninger EM, Rangareddy M, Veeraraghavan S, et al. Long-term
- outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI.
 Nephrol Dial Transplant. 2023.
- 516 19. Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health
- 517 Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health 518 Technol Inform. 2015;216:574-8.
- 519 20. Rao A, Ranka S, Ayers C, Hendren N, Rosenblatt A, Alger HM, et al. Association of Kidney
- 520 Disease With Outcomes in COVID-19: Results From the American Heart Association COVID-19 521 Cardiovascular Disease Registry. J Am Heart Assoc. 2021;10(12):e020910.
- 522 21. Ye X, Ma T, Blais JE, Yan VKC, Kang W, Chui CSL, et al. Association between BNT162b2 or 523 CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with
- 523 CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with 524 cardiovascular disease. Cardiovasc Res. 2022;118(10):2329-38.
- 525 22. Musheyev B, Janowicz R, Borg L, Matarlo M, Boyle H, Hou W, et al. Characterizing non-
- 526 critically ill COVID-19 survivors with and without in-hospital rehabilitation. Sci Rep. 2021;11(1):21039.
- Musheyev B, Borg L, Janowicz R, Matarlo M, Boyle H, Singh G, et al. Functional status of
 mechanically ventilated COVID-19 survivors at ICU and hospital discharge. J Intensive Care.
- 529 2021;9(1):31.
- 530 24. Musheyev B, Boparai MS, Kimura R, Janowicz R, Pamlanye S, Hou W, et al. Longitudinal
 531 medical subspecialty follow-up of critically and non-critically ill hospitalized COVID-19 survivors up to
 532 24 months after discharge. Intern Emerg Med. 2023:1-10.
- 533 25. Lavery AM PL, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, Kompaniyets L, Datta SD,
- 534 Click ES, Golden T, Goodman AB, Mac Kenzie WR, Boehmer TK, Gundlapalli AV. Characteristics of
- Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission United
 States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695-9.
- 537 26. Patel S TG, Rajan A, Creech Z, Walters R, Ng I, Destache C, Vivekanandan R, Tierney M,
- Velagapudi M. Discharge Disposition and Clinical Outcomes of Patients Hospitalized with COVID-19.
 Int J Infect Dis. 2023:S1201-9712(23)00040-1.
- 540 27. Ayoubkhani D KK, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-covid
 541 syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ Open.
 542 2021;372.
- 543 28. Sotoodeh Ghorbani S TN, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic
- characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A
 systematic review and meta-analysis. J Med Virol. 2022;94(1):44-53.
- 546 29. Alanli R KM, Yalcin KS. Readmission rates of patients with COVID-19 after hospital discharge.
 547 Rev Assoc Med Bras (1992). 2021;67(11):1610-5.
- 548 30. Freire MP OM, Magri MMC, Tavares BM, Marinho I, Nastri ACSS, Filho GB; HCFMUSP
- 549 COVID-19 Study Group; Levin AS. Frequency and factors associated with hospital readmission after
- 550 COVID-19 hospitalization: the importance of post-COVID diarrhea. Clinics (Sao Paulo).
- 551 2022;77:100061.
- 552 31. Tobler DL PA, Naderi S, Ambrosy AP, Slade JJ. Long-Term Cardiovascular Effects of COVID-
- 19: Emerging Data Relevant to the Cardiovascular Clinician. Curr Atheroscler Rep. 2022;24(7):563-70.
- 554 32. Silva Andrade B SS, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A,
- 555 Ribeiro da Silveira P, Tiwari S, Alzahrani KJ, Góes-Neto A, Azevedo V, Ghosh P, Barh D. Long-COVID
- and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their
- 557 Possible Molecular Mechanisms. Viruses. 2021;13(4):700.

- 558 33. Mohammad KO LA, Rodriguez JBC. Cardiac Manifestations of Post-Acute COVID-19 Infection. 559 Curr Cardiol Rep. 2022;24(12):1775-83.
- 560 34. Lawandi A WS, Sun J, Demirkale CY, Danner RL, Klompas M, Gundlapalli A, Datta D, Harris
- 561 AM, Morris SB, Natarajan P, Kadri SS, Suspected Severe Acute Respiratory Syndrome Coronavirus 2
- 562 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US
- 563 Healthcare Facilities, 1 June 2020 to 28 February 2021. Clin Infect Dis. 2022;74(8):1489-92.
- 564 Slezak J BK, Fischer H, Broder B, Ackerson B, Tartof S. Rate and severity of suspected SARS-35.
- 565 Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin Microbiol Infect.
- 566 2021;27(12):1860.e7-.e10.
- 567 Khanijahani A IS, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review of 36. 568 racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021;20(1):248.
- 569 37. Haitao T VJ, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, Narang K, Parashuram
- 570 S, Suvakov S, Garovic VD. COVID-19 and Sex Differences: Mechanisms and Biomarkers. Mayo Clin 571 Proc. 2020;95(10):2189-203.
- 572 Fabião J SB, Pedrollo EF, Gerchman F, Kramer CK, Leitão CB, Pinto LC. Why do men have 38.
- 573 worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age.
- 574 Braz J Med Biol Res. 2022;55:e11711.
- 575 Attaway AH SR, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis 39. 576 and clinical management. BMJ Open. 2021;372:n436.
- 577 Gao YD DM, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang 40.
- 578 HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis
- 579 CA. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.
- 580 Douaud G LS, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, Lange F, Andersson JLR, 41.
- 581 Griffanti L, Duff E, Jbabdi S, Taschler B, Keating P, Winkler AM, Collins R, Matthews PM, Allen N,
- 582 Miller KL, Nichols TE, Smith SM, SARS-CoV-2 is associated with changes in brain structure in UK
- 583 Biobank. Nature. 2022;604(7907):697-707.
- 584 Lu Y LX, Geng D, Mei N, Wu PY, Huang CC, Jia T, Zhao Y, Wang D, Xiao A, Yin B. Cerebral 42. 585 Micro-Structural Changes in COVID-19 Patients - An MRI-based 3-month Follow-up Study.
- 586 EClinicalMedicine. 2020;25:100484.
- 587 Hellgren L BTU, Samuelsson K, Levi R, Divanoglou A, Blystad I. Brain MRI and 43.
- 588 neuropsychological findings at long-term follow-up after COVID-19 hospitalisation: an observational 589 cohort study. BMJ Open. 2021;11(10).
- 590 44. Huang S ZZ, Yang D, Zhao W, Zeng M, Xie X, Du Y, Jiang Y, Zhou X, Yang W, Guo H, Sun H, 591 Liu P, Liu J, Luo H, Liu J. Persistent white matter changes in recovered COVID-19 patients at the 1-year
- 592 follow-up. 2022;145(5):1830-8.
- 593 45. Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al. Cerebral Micro-Structural Changes in
- 594 COVID-19 Patients - An MRI-based 3-month Follow-up Study. EClinicalMedicine. 2020;25:100484.
- 595 46. Hellgren L, Birberg Thornberg U, Samuelsson K, Levi R, Divanoglou A, Blystad I. Brain MRI
- 596 and neuropsychological findings at long-term follow-up after COVID-19 hospitalisation: an observational 597 cohort study. BMJ Open. 2021;11(10):e055164.
- Huang S ZZ, Yang D, et al. Persistent white matter changes in recovered COVID-19 patients at 598 47. 599 the 1-year follow-up. Brain. 2022;145(5):1830-8.
- 600 48. Moghimi N, Di Napoli, M., Biller, J., Siegler, J. E., Shekhar, R., McCullough, L. D., Harkins, M.
- 601 S., Hong, E., Alaouieh, D. A., Mansueto, G., & Divani, A. A. The Neurological Manifestations of Post-
- 602 Acute Sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021;21(9).
- 603 Graham EL CJ, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov 49.
- 604 R, Ho SU, Batra A, Liotta EM, Koralnik IJ. Persistent neurologic symptoms and cognitive dysfunction in
- 605 non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol. 2021;8(5):1073-85.
- 606 50. Wang F KR, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med
- 607 Sci Monit. 2020;26:e928996.

609	Table 1. Demographics,	comorbidities,	and outcomes	of survivor	patients in t	the neurological ar	d control
					<u> </u>	-	

610	cohorts. Mean±SD or n (%). * p<0.05, ** p<0.0	l, *** p<0.001 between the	neurological and control
611	cohorts.	-	-

		0 + 10 1 +
	Neurologic Cohort	Control Cohort
	(N=414)	(N=1199)
Patient Characteristics		
Age, years old (at admission)	69.71±15.80	70.26±15.14
Female (%)	186 (44.93%)	578 (48.21%)
Combined Race and Ethnicity		
White, not Hispanic	27 (6.52%)	94 (7.84%)
Black, not Hispanic	176 (42.51%)	432 (36.03%)***
Hispanic	139 (33.57%)	458 (38.20%)*
Other	62 (14.98%)	169 (14.10%)
Comorbidities (at admission)		
Hypertension	186 (44.93%)	523 (43.62%)
COPD/Asthma	42 (10.14%)	144 (12.01%)
Diabetes	126 (30.43%)	343 (28.61%)
CHF	49 (11.84%)	118 (9.84%)
СКД	90 (21.74%)	223 (18.60%)
Discharge Disposition		
Home	208 (50.24%)	799 (66.64%)***
Acute Rehab	43 (10.39%)	40 (3.34%)***
SNF	148 (35.75%)	304 (25.35%)***
Hospice	6 (1.45%)	15 (1.25%)
Other	9 (2.17%)	41 (3.42%)
Outcomes (Jan 10, 2023)		
Hospital Readmission	272 (65.70%)	728 (60.72%)*
Stroke	26 (6.28%)	28 (2.34%)***
Heart Attack	22 (5.31%)	50 (4.17%)
MACE	85 (20.53%)	198 (16.51%)*
Mortality after discharge		· · ·
0.5 years	32 (7.73%)	44 (3.67%)***
1.0 years	38 (9.18%)	59 (4.92%)***
3.0 years	58 (14.01%)	94 (7.84%)***
SARS-CoV-2 reinfection	18 (4.35%)	55 (4.59%)

- **Table 2.** Primary cause of death of patients who died after discharge. * p<0.05, ** p<0.01, *** p<0.001
- 615 between the neurological and control cohorts.

616

617

Cause of Death	Neurological	Control
	(N=58)	(N=94)
Unknown	16 (27.59%)	31 (34.07%)
Heart Disease	8 (13.79%)	14 (15.38%)
Sepsis	5 (8.62%)	16 (17.58%)
Influenza and Pneumonia	8 (13.79%)	9 (9.89%)
COVID-19	6 (10.34%)	7 (7.69%)
ARDS, Hypoxia	6 (10.34%)	6 (6.59%)
Other (GI Bleed, Pancreatitis, ICH, Acute Liver Failure)	3 (5.17%)	6 (6.59%)
Cancer	2 (3.45%)	2 (2.20%)
Nephritis, Nephrotic Syndrome, and Nephrosis	2 (3.45%)	1 (1.10%)
Stroke (Cerebrovascular Diseases)	1 (1.72%)	1 (1.10%)
Accidents (Unintentional Injuries)	1 (1.72%)	1 (1.10%)

- 619 **Table 3.** (A) Demographics and comorbidities of patients who died versus survived after discharge in the
- 620 neurological and control cohorts. Patients lost to follow up were excluded. Mean±SD or n (%). * p<0.05,
- 621 ** p<0.01, *** p<0.001 between survivors or non-survivors in the neurological and control cohorts. ^

622 p<0.05, ^^ p<0.01, ^^^ p<0.001 between survivors and non-survivors in the same cohort. (B) Odds ratios

623 of mortality post discharge.

(A)	Neurological Cohort (N=371)		Control Cohort (N=1043)		
	Survivors N=313 (84.37%)	Non-survivors N=58 (15.63%)	Survivors N=949 (90.99%)	Non-survivors N=94 (9.01%)	
Patient Characteristics					
Age, year old (at admission)	67.85±15.85	76.40±11.71***	69.20±14.95	76.56±11.23***	
Female	147 (46.96%)	22 (37.93%)	480 (50.58%)	43 (45.74%)	
Combined Race and Ethnicity					
White, non-Hispanic	23 (7.35%)	3 (5.17%)	68 (7.17%)	9 (9.57%)	
Black, non-Hispanic	129 (41.21%)	28 (48.28%)	350 (36.88%)	42 (44.68%)	
Hispanic	106 (33.87%)	19 (32.76%)	383 (40.36%)	39 (41.49%)	
Other	47 (12.02%)	5 (8.62%)	139 (14.65%)	3 (3.19%)***	
COVID-19 Severity Score	3.32±2.02	4.40±1.79	3.36±2.06^	4.74±2.05***,^^	
Comorbidities (at admission)					
Hypertension	151 (48.24%)	31 (53.45%)	456 (48.05%)	54 (57.45%)*	
COPD/Asthma	35 (11.18%)	6 (10.34%)	128 (13.49%)	17 (18.09%)	
Diabetes	100 (31.95%)	21 (36.21%)	298 (31.40%)	39 (41.49%)*	
Congestive heart failure	38 (12.14%)	11 (18.97%)	83 (8.75%)	31 (32.98%)***,^	
Chronic kidney disease	75 (23.96%)	14 (24.14%)	185 (19.49%)	36 (38.30%)***	
Discharge Disposition					
Home	173 (55.27%)	17 (29.31%)***	686 (72.29%)^^^	38 (40.43%)***	
Acute Rehab	33 (10.54%)	7 (12.07%)	36 (3.79%)^^^	4 (4.26%)	
SNF	96 (30.67%)	32 (55.17%)***	203 (21.39%)^^	39 (41.49%)***	
Hospice	2 (0.64%)	2 (3.45%)	1 (0.11%)	4 (4.26%)***	
Other	9 (2.88%)	0 (0.00%)	23 (2.42%)	9 (9.57%)***	

(B)	OR	95% CI	p-val
Belonging to Neurological Cohort	1.802	(1.237, 2.608)	0.002
Discharge disposition	1.508	(1.276, 1.775)	<0.0001
Congestive heart failure	2.281	(1.429, 3.593)	0.0004
COVID-19 Severity Score	1.177	(1.062, 1.304)	0.002
Age	1.027	(1.010, 1.044)	0.002
Male	1.387	(0.963, 2.004)	0.080
Chronic kidney disease	1.321	(0.849, 2.039)	0.213
Diabetes	1.131	(0.744, 1.710)	0.561
COPD/Asthma	1.130	(0.651, 1.892)	0.652
Hypertension	0.985	(0.649, 1.492)	0.942

- 626 **Table 4.** Imaging findings pre, during, and post-COVID-19 infection. The neurological cohort had pre-
- and post-COVID-19 imaging at 456±729 days and 335±274 days before and after hospitalization,
- 628 respectively. The control cohort had pre- and post-COVID-19 imaging at 828±974 and 432±300 days
- 629 before and after hospitalization, respectively. Patients who died during COVID-19 hospitalization are
- 630 excluded. Studies were scored as 0 (normal or no abnormality), 1 (mild abnormality), 2 (moderate
- 631 abnormality), and 3 (severe abnormality).


	Pre COVID-19		During COVID-19			Post COVID-19			
	Neurological	Control	p-val	Neurological	Control	p-val	Neurological	Control	p-val
Total Patients	94	143		65	32		144	251	
MRI	21 (22.34%)	32 (22.38%)	1.000	6 (9.23%)	6 (18.75%)	0.312	32 (21.92%)	67 (26.69%)	0.386
СТ	73 (77.66%)	111 (77.62%)	1.000	59 (90.77%)	26 (81.25%)	0.312	112 (76.71%)	184 (73.31%)	0.386
Qualitative Findings									
Hemorrhage	4 (4.26%)	3 (2.10%)	0.570	5 (7.69%)	0 (0%)	0.262	7 (4.86%)	7 (2.79%)	0.430
Active Stroke	6 (6.38%)	7 (4.90%)	0.841	7 (10.77%)	2 (6.25%)	0.727	11 (7.64%)	12 (4.78%)	0.345
Prior Stroke	35 (37.23%)	43 (30.07%)	0.314	23 (35.38%)	11 (34.38%)	1.000	58 (40.28%)	76 (30.28%)	0.056
Mass Effect	2 (2.13%)	7 (4.90%)	0.457	6 (9.23%)	2 (6.25%)	0.913	10 (6.94%)	14 (5.58%)	0.743
Microhemorrhage	5 (5.32%)	8 (5.59%)	1.000	5 (4.62%)	0 (0%)	0.262	9 (6.25%)	17 (6.77%)	1.000
Scoring Findings									
White Matter Change	0.99±0.81	0.93±0.75	0.572	$0.97{\pm}0.78$	1.13±0.89	0.411	1.06±0.86	1.05±0.84	0.942
0	27 (28.72%)	41 (28.67%)	1.000	18 (27.69%)	7 (21.88%)	0.712	39 (27.08%)	66 (26.69%)	0.958
1	45 (47.87%)	76 (53.15%)	0.508	34 (52.31%)	18 (56.25%)	0.881	67 (46.53%)	122 (48.61%)	0.769
2	18 (19.15%)	21 (14.69%)	0.467	10 (15.38%)	3 (9.38%)	0.617	28 (19.44%)	47 (18.73%)	0.966
3	4 (4.26%)	5 (3.50%)	1.000	3 (4.62%)	4 (12.50%)	0.320	10 (6.94%)	16 (6.37%)	0.993
Microvascular Disease	0.95±0.78	0.89±0.75	0.566	$0.94{\pm}0.80$	1.16±0.87	0.246	1.05±0.84	1.04±0.83	0.922
0	28 (29.79%)	45 (31.47%)	0.896	20 (30.77%)	6 (18.75%)	0.311	39 (27.08%)	67 (26.69%)	1.000
1	46 (48.94%)	73 (51.05%)	0.853	32 (49.23%)	19 (59.38%)	0.469	68 (47.22%)	123 (49.00%)	0.813
2	17 (18.09%)	21 (14.69%)	0.605	10 (15.38%)	3 (9.38%)	0.617	28 (19.44%)	46 (18.33%)	0.889
3	3 (3.19%)	4 (2.80%)	1.000	3 (4.62%)	4 (12.50%)	0.320	9 (6.25%)	15 (5.98%)	1.000
Volume Loss	0.55±0.68	0.48±0.59	0.412	0.63±0.67	0.66±0.77	0.876	0.72±0.71	0.57±0.69	0.045
0	51 (54.26%)	81 (56.64%)	0.819	31 (47.69%)	16 (50.00%)	1.000	61 (42.36%)	135 (53.78%)	0.037
1	35 (37.23%)	55 (38.46%)	0.957	27 (41.54%)	12 (37.50%)	0.872	63 (43.75%)	89 (35.46%)	0.128
2	7 (7.45%)	7 (4.90%)	0.594	7 (10.77%)	3 (9.38%)	1.000	19 (13.19%)	26 (10.36%)	0.491
3	1 (1.06%)	0 (0%)	0.832	0 (0%)	1 (3.13%)	0.716	1 (0.69%)	1 (0.40%)	1.000
White Matter Hyperintensity/Lesion	0.62±0.50	0.38±0.28	0.338	1±0.38	0.33±0.24	0.645	0.41±0.39	0.49±0.43	0.333
0	13 (13.83%)	20 (13.99%)	1.000	2 (3.08%)	4 (12.50%)	0.173	23 (15.97%)	41 (16.33%)	1.000
1	4 (4.26%)	12 (8.39%)	0.329	2 (3.08%)	2 (6.25%)	0.845	6 (4.17%)	21 (8.37%)	0.166
2	3 (3.19%)	0 (0%)	0.120	2 (3.08%)	0 (0%)	0.808	2 (1.39%)	3 (1.20%)	1.000
3	1 (1.06%)	0 (0%)	0.832	0 (0%)	0 (0%)	NA	1 (0.69%)	2 (0.80%)	1.000

- 633 **Table 4B.** Changes in imaging findings between baseline (pre or during COVID-19 hospitalization) and
- 634 follow-up (post-COVID-19 hospitalization). Only patients with both a baseline and follow-up scan were
- 635 included. Studies were scored as 0 (normal or no abnormality), 1 (mild abnormality), 2 (moderate
- 636 abnormality), and 3 (severe abnormality).


	Neurological (N=112)		Control (N=157)				
		p-val		p-val	p-val (neurological vs		
		_			control)		
Changes in incidence for							
Hemorrhage	3 (2.68%)	0.245	3 (1.91%)	0.246	0.999		
Active Stroke	7 (6.25%)	0.021	6 (3.82%)	0.039	0.531		
Prior Stroke	14	0.0003	15 (9.55%)	0.0002	0.570		
Mass Effect	5 (4.46%)	0.070	4 (2.55%)	0.131	0.605		
Microhemorrhage	8 (7.14%)	0.012	10 (6.37%)	0.004	0.998		
Changes in scores for							
White Matter Change	0.12±0.44	0.006	0.18±046	<0.0001	0.219		
Microvascular Disease	0.15±0.41	0.0001	0.18 ± 046	<0.0001	0.538		
Volume Loss	0.15±0.41	0.0001	0.17 ± 0.42	<0.0001	0.787		
White Matter	-0.04 ± 0.63	0.459	0.03 ± 0.42	0.452	0.310		
Hyperintensity/Lesion							

Figure 1. Percent of patients in the neurological and control cohorts discharged to home, acute

rehabilitation, skilled nursing facility (SNF), hospice, and others for different COVID-19 severity score.



- 643 Figure 2. Kaplan-Meier Survival Curve analyzing the probability of survival after discharge from
- 644 COVID-19 hospitalization in the neurological cohort versus the control cohort. HR = 2.346, 95%
- 645 CI=(1.586, 3.470), p-value<0.0001.




648 **Supplemental Table 1**. Laboratory values of neurological and control patients at COVID-19

- 649 hospitalization admission and most recent follow-up. Mean±SD or n (%). * p<0.05, ** p<0.01, ***
- p < 0.001 between the neurological and control cohorts. ^ p < 0.05, ^ p < 0.01, ^ p < 0.001 between
- admission and follow-up lab values within the same cohort.
- 652


	Neurologic (N=41		Control Cohort (N=1199)		
Lab Values	Admission	Follow-Up	Admission	Follow-Up	
Temperature [°F]	98.86±1.22^^^	98.22±0.74	99.05±1.33^^^,**	98.11±2.05	
SBP [mmHg]	133.64±27.46^^^	124.19±24.44	135.09±25.25^^^	127.24±22.49*	
Mean arterial pressure [mmHg]	122.38±83.16	116.77±61.21	103.33±65.24^^^,***	111.56±63.52	
DDIM [ug/mL FEU]	4.27±5.57^^^	3.17±4.42	3.46±4.84**	3.05±14.05	
INR [seconds]	15.75±7.00	15.48±4.48	15.32±6.82	15.38±4.99	
BUN [mg/dL]	35.35±35.08^^^	26.26±24.06	29.94±28.38^^^,**	22.64±20.52**	
Cr [mg/dL]	2.15±2.74^	1.79±2.27	1.90±2.43^^^	1.57±1.90*	
Sodium	138.58±8.07	139.18±4.85	137.75±7.48^^^	139.10±4.30	
Glucose [mg/dL]	190.21±179.35^^^	136.47±74.92	172.68±135.56^^^,*	130.12±62.67	
AST [U/L]	48.76±53.08	61.20±257.39	56.87±105.55*	52.89±361.85	
ALT [U/L]	33.8544.55	51.74±267.41	38.82±71.60*	36.96±102.81	
WBC [k/uL]	8.13±4.67	7.95±3.99	8.47±7.31^^	7.91±3.66	
Lymph [k/uL]	1.16±0.76^^^	1.67±0.93	1.38±4.94^^	1.74±1.09	
FERR [ng/mL]	1251.76±1550.73^	964.16±2385.43	1261.31±2092.20^^^	948.88±1532.12	
CRP [mg/L]	9.61±9.33^^^	5.91±6.94	11.10±9.66^^^,**	5.54±6.27	
Procalcitonin [ug/L]	1.99±6.17	2.23±7.15	1.25±4.82*	1.43±6.10*	
LDH [U/L]	411.72±300.88^^^	345.73±156.67	404.41±231.39^^^	341.15±267.74	
BNP [pg/mL]	2519.11±4491.13^^^	1642.03±3577.47	1825.85±3716.69^^^*,*	1242.17±2948.39*	
TNT [ug/L]	0.06±0.19^	0.26±2.13	0.04±0.09^^^,*	0.18±1.53	
Pulse Oximetry [% Oxygenation]	95.20±5.51^^^	97.10±6.31	93.80±7.15^^^,***	97.12±5.56	

654 **Supplemental Figure 1.** (A) Distribution of COVID-19 severity score in the neurological and control 655 cohorts (survivors after COVID-19 hospitalization discharge). Percent of patients in the neurological and

- 656 control cohorts who (B) were readmitted, (C) had stroke, (D) had heart attack, (E) had MACE, and (F)
- died after discharge from COVID-19 hospitalization.



Discharge Disposition: Neurological Cohort





Discharge Disposition: Control Cohort






Figure 1

Kaplan-Meier Survival Analysis








Figure 2








9





25






Heart Attack After Discharge: Control Cohort

8


9

10


MACE After Discharge: Control Cohort









Readmission After Discharge: Control Cohort




Stroke After Discharge: Control Cohort





Mortality After Discharge: Control Cohort



Supplemental Figure 1